|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Overexpression and gain-of-function mutations in EZH2 are regarded as oncogenic drivers in lymphoma and other malignancies due to the silencing of tumor suppressors and differentiation genes.
|
31419226 |
2019 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Enhancer of zeste homolog 2 (EZH2) and Bcl-2 gene rearrangement or protein upregulation played pivotal roles in the carcinogenesis of various malignancies including lymphomas.
|
31205561 |
2019 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutation of EZH2 Y641 is described in lymphoma and results in enhanced activity, whereas inactivating mutations are seen in poor prognosis myeloid neoplasms.
|
21367748 |
2011 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The reduction of CSC self-renewal via EZH2 inhibition offers a potentially attractive therapeutic approach to counter the aberrant activation found in lymphoma and leukemia.
|
24097338 |
2014 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas.
|
24052547 |
2013 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This represents the first example of a disease-associated gain-of-function mutation in a histone methyltransferase, whereby somatic EZH2 Y641 mutations in lymphoma act dominantly to increase, rather than decrease, histone methylation.
|
21190999 |
2011 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We observed a dramatic acceleration of lymphoma development in this combination model of Myc and EZH2(Y641F).
|
24802772 |
2014 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Direct binding of MALAT1 to the PRC2 components (EZH2 and SUZ12) was observed in a T cell lymphoma cell line; however, no direct binding of MALAT1 with H3K27me3 and BMI1 (a PRC1 component) was observed.In T and NK cell lymphomas, MALAT1 was related to poor prognosis.
|
28412742 |
2017 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We discovered that YC-1 induces apoptosis and inhibits tumour growth of breast cancer cells via down-regulation of EZH2 by activating c-Cbl and ERK.
|
24697523 |
2014 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutations associated with disease progression such as isocitrate dehydrogenase (IDH) 1, IDH2, EZH2, serine/arginine-rich splicing factor 2 (SRSF2), p53, casitas B-lineage lymphoma (c-CBL), ikaros zinc fingers (IKZF), neurofibromin 1 (NF1) and runt-related transcription factor 1 (RUNX1) are described.
|
23298878 |
2013 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Enhancer of zeste homolog 2 (EZH2), an H3K27-specific histone methyltransferase, has been shown to be frequently overexpressed in various human cancers including lymphoma.
|
30218753 |
2019 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
EZH2, as transcriptional repressor, is mutated in high frequency in Chinese and Western patients with follicular lymphoma and may represent a rational target for GC-derived lymphomas..
|
24857928 |
2014 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The antitumor efficacy of pharmacological EZH2 inhibition depends on SESTRIN1, indicating that mTORC1 control is a critical function of EZH2 in lymphoma.
|
28659443 |
2017 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
These EZH2 mutations may drive the proliferation of lymphoma and make EZH2 a molecular target for patients harboring these mutations.
|
22850114 |
2012 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
|
23023262 |
2012 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Importantly, the EZH2(Y641) mutants recurrently implicated in lymphoma pathogenesis are unable to bind β-TrCP.
|
24469040 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Our findings support the clinical translation of the combination of EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.
|
30979734 |
2019 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
EZH2 mutations were frequently associated with the presence of BCL2 rearrangement (BCL2-R) in both the FL (28% of BCL-R cases versus 0% of BCL2-WT cases, p<0.05) and GCB-DLBCL groups (33% of BCL2-R cases versus 4% of BCL2-WT cases, p<0.04), and across all lymphoma types excluding BL (27% of BCL2-R cases versus 3% of BCL2-WT cases, p<0.003).
|
22194861 |
2011 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Insights into their biological mechanisms led to the development of therapies designed to target mutant IDH1 and IDH2, DOT1L in MLL-rearranged leukemias and EZH2 in several cancer types including lymphomas.
|
25942537 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In this review, we present the rationale, key pre-clinical and early clinical findings of small molecule EZH2 inhibitors for use in lymphoma as well as future challenges and potential opportunities for combination therapies.
|
29473431 |
2018 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma.
|
30112706 |
2018 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 axis, resulting in restoration of miR-29 expression, downregulation of miR-29-targeted genes, and lymphoma growth suppression in vitro and in vivo.
|
23079660 |
2012 |
|
Lymphoma
|
0.500 |
CausalMutation
|
group |
CGI |
|
|
|
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas.
|
23051747 |
2012 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
|
24563539 |
2014 |